Imiphumela ye-US neYurophu Yokulinganisa Evezwe i-Glucosamine
E-American College of Rheumatology Annual Scientific Meeting (2005), kwavela imiphumela emibili yokuhlolwa kwe- glucosamine . Imiphumela yezilingo ezimbili zazikulindelwe kakhulu abacwaningi, odokotela, neziguli ezazifuna ukuqinisekiswa ukuthi i-glucosamine yindlela yokwelapha ekwazi ukubhekana ne-arthritis .
- I-GAIT (Glucosamine / Chondroitin I-Arthritis Intervention Trial) yaxhaswa yiNational Institutes of Health futhi yenzelwe ukunquma ukuphepha nokuphumelela nge-glucosamine ne- chondroitin , ethathwe ngokwahlukana noma ndawonye.
- UMHLAHLANDLELO (Glucosamine Unum In Die Efficacy) kwakuyivivinyo laseMyriphu.
I-GAIT (Glucosamine / Chondroitin I-Arthritis Intervention Trial) Isigaba I
Ku-GAIT (Glucosamine / Chondroitin I-Arthritis Intervention Trial), iziguli ezingaba ngu-1 600 ezine- osteoarthritis ezibuhlungu zibuyiselwa ezifundweni ezingu-16 zase-US zezifundo zengqondo. Abahlanganyeli bokutadisha babethole ubuhlungu obunzima begciwane futhi babe nobufakazi be -x-ra of kneearthritis. Phakathi nesifundo se-GAIT, iziguli:
- Babehlolwe ekuqaleni kokucwaninga.
- Kwahlolwa emavikini 4, 8, 16, 24.
- Iziguli zazingenangqondo ukuthola i-glucosamine HCl, i-sodium chondroitin sulfate, izithako zombili, i- celecoxib (igama elithi brand Celebrex) , noma i-placebo.
- Iziguli zavunyelwa ukufika ku-4,000 mg nsuku zonke ze-acetaminophen.
Imiphumela Evela ku-GAIT (Glucosamine / Chondroitin Arthritis Intervention Trial)
- Imiphumela yabonisa ukuthi inhlanganisela ye-glucosamine ne-chondroitin ingcono kune-placebo kodwa izinzuzo zibonakala zixhomeke ebukhulu bezinhlungu.
- Ezigulini ezinomzimba ophuthumayo we-osteoarthritis we-knee, 79.2% ukuthatha inhlanganisela yezinhlungu ezihlangene ezibuhlungu.
- Iziguli ezithatha i-celecoxib, ukuphulukiswa kobuhlungu obunamahloni angu-69.4%. Kulezi ziguli ezithatha i-glucosamine yedwa, ama-65.7% athola usizo, njengoba kwenza iziguli ezingu-61.4 zithatha i-chondroitin yedwa. Futhi, u-54.3% ethatha indawo ye-placebo ubike ukukhululeka kobuhlungu.
- Ezigulini ezinobunzima bomzimba we-knee osteoarthritis, inhlanganisela ye-glucosamine / chondroitin ayizange iphumelele kakhulu kune-placebo.
Isiqondiso (Glucosamine Unum In Die Efficacy)
Kwakukhona iziguli ezingu-318 esifundweni se-GUIDE nge-knee osteoarthritis (abesifazane abangu-88%). Iziguli zazingenakulinganiswa ukuthatha noma i-oral glucosamine sulfate soluble powder (1500 mg kanye ngosuku), i- acetaminophen (1000 mg kathathu ngosuku), noma i-placebo ngaphezu kwenyanga-6. Wonke amaqembu avunyelwe ukuthatha ibuprofen njengoba kudingeka.
Imiphumela esuka ku-GUIDE (i-Glucosamine Unum In Die Efficiency)
- Kokubili i-glucosamine sulfate ne-acetaminophen zaziphumelela kakhulu ekunciphiseni ubuhlungu kune-placebo.
- Iziguli ezithatha i-glucosamine sulfate zabonisa ukukhululeka okungaphezu kweziguli ezise-acetaminophen.
- Kwaqedelwa ukuthi ukwelashwa komlomo we-glucosamine sulfate nge-1500 mg ngosuku kungaba yindlela yokwelashwa ye-knee osteoarthritis.
Isigaba II nesigaba III I-GAIT Imiphumela
Imiphumela evela kwesigaba sesibili socwaningo lwe-GAIT yanyatheliswa encwadini ye- Arthritis & Rheumatism ngo-2008. Isigaba II sihlolisisa ukuhlanganiswa kwe-glucosamine ne-chondroitin ngokuvimbela ukulimala okuhlangene kwamadolo. Inhlanganisela ye-glucosamine ne-chondroitin yayingabonakali ephumelelayo ekuvimbeleni umonakalo ohlangene ohlobene ne-osteoarthritis kune-placebo.
Abahlanganyeli be-Study abalahlekelwa isikhala esincane esincane sokuhlangana ngaphezu kweminyaka emibili babephakathi kwamaqembu athatha i-glucosamine noma i-chondroitin yedwa. Mhlawumbe, ukuthatha izithako ezimbili ndawonye kuthinta ukumuncwa, okungase kuchaze ukusebenza okuncane kwezinsiza lapho kusetshenziswa inhlanganisela.
Isigaba III, esabhekana nesamba seminyaka emine yedatha, sambule ukuthi izithako ezihlanganisiwe noma zodwa azizuzizuzisa kakhulu ukuphumula kobuhlungu kunama-celecoxib noma i-placebo. Imiphumela yanyatheliswa ngo-2010 encwadini ye- Annals of Rheumatic Disease .
Incomo ye-Glucosamine
- Ngaphambi kokuzama i-glucosamine / chondroitin ukuxoxisana nodokotela wakho bese ubuza ukuthi kuzohambisana kanjani nohlelo lwakho lwamanje lwezokwelapha.
- Hlala emithini yakho enqunyiwe. Izithako azihambisani nemithi enqunyiwe.
- Funda nge-glucosamine ngokwenza ucwaningo lwakho siqu. Thola imithombo yolwazi enokwethenjelwa.
- Landela izinkomba ezichazwe ngumkhiqizi wengezela noma ubuze udokotela wakho mayelana nesilinganiso esifanele.
- Gwema ukuhlanganisa ezinye izithako ezihlukahlukene.
- Thenga kusuka kumkhiqizi ohloniphekile. Yazi ukuthi utholaphi.
Okubalulekile
Ngo-2012, i-American College of Rheumatology yanyathelisa izincomo zokwelapha ze-osteoarthritis. Kulezi ziqondiso, i-chondroitin noma i-glucosamine ayinganyelwanga ukwelashwa kokuqala kwe-osteoarthritis. Izithako ze-Chondroitin ne-glucosamine zodwa noma ngokuhlanganiswa kungenzeka zingabi ukwelashwa okuphumelelayo kuzo zonke iziguli. Kungase isebenze iziguli ezithile, futhi uma isebenza kuwe, qhubeka nokuphathwa - kubhekwa njengokuphephile.
Imithombo:
Umphumela we-glucosamine kanye / noma i-chondroitin sulfate ekuqhubeni kwe-knee osteoarthritis: umbiko ovela enkantolo yokungenelela kwe-glucosamine / chondroitin arthritis. Sawitzke et al. I-arthritis ne-Rheumatism. 2008 Oct; 58 (10): 3183-91.
http://www.ncbi.nlm.nih.gov/pubmed/18821708
I-Glucosamine / Chondroitin I-Arthritis Intervention Trial (GAIT). I-NIH. Ishintshiwe ngoJanuwari 2012.
https://nccih.nih.gov/research/results/gait
Ukusebenza komtholampilo nokuphepha kwe-glucosamine, i-chondroitin sulphate, inhlanganisela yabo, i-celecoxib noma i-placebo ethathwe ukuphatha i-osteoarthritis yamadolo: imiphumela emibili yeminyaka esuka ku-GAIT. Juni 2010. Amalengiso we-Rheumatic Disease. 2010; 69: 1459-1464
http://ard.bmj.com/content/69/8/1459.abstract?sid=fc95aeb7-1d79-4a79-9dac-c65916ca2125
Izincomo zokusetshenziswa kwe-Nonpharmacologic ne-Pharmacologic Therapies e-Osteoarthritis ye-Hand, Hip, ne-Knee.I-American College of Rheumatology 2012. (Arthritis Care & Research Vol. 64, No. 4, Ephreli 2012, iphe. 465-474.)